Measuring hCG Levels in Pregnant Women

hCG Clinical Trial

Official title:

Measuring hCG Levels in Pregnant Women: a Prenatal Study of hCG Using MLPT and Serum Testing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02763176
• Other study ID #: 6007
• Status: Completed
• Start date: July 2016
• Est. completion date: June 2018

Study information

• Verified date: June 2018
• Source: Gynuity Health Projects
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study seeks to assess trends in hCG between the 9th and 12th weeks of gestation. Women presenting at prenatal care at the study site who are 70 days gestation or less will be offered participation in the study. 75 consenting women will be asked to provide urine for an MLPT and to have blood drawn for hCG serum testing at 56-63 days, 64-70 days, and 71-77 days' gestation, and 75 consenting women will be asked to provide urine for an MLPT and to have blood drawn for hCG serum testing at 64-70 days, 71-77 days, and 78-84 days' gestation.

Description:

Women presenting at the study site for a prenatal visit, and who are ≤ 70 days' gestation, will be offered participation in the study. Efforts will also be made to recruit patients through physician or treating health care professional referral and advertisements. One hundred and fifty consenting women will be enrolled. Up to three additional study visits will be scheduled: At the enrollment, if an ultrasound-confirmed gestational age is not available in the woman's medical record, a transvaginal ultrasound will be performed. If the woman is 56-63 days gestation on the day of enrollment, she will be asked to return weekly until she reaches 71-77 days. If the woman is 64-70 days gestation, she will be asked to return weekly until she reaches 78-84 days. If the woman is less than 56 days gestation, she will be asked to return for the three research visits at the appropriate time to provide the urine samples and blood draws. Women will have one visit during each of their three assigned gestational age weeks. At each visit, women will provide a urine sample for an MLPT and have a blood draw to measure serum hCG.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: June 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Intrauterine pregnancy <= 70 days' gestation

• Be in general good health

• English speaking competency

• Be willing and able to sign consent forms

• Agree to comply with the study procedures, including returning for three study visits that each involve a blood draw and urine pregnancy test for measuring hCG

Exclusion Criteria:

• Women less than 18 years of age.

• Any women not meeting the inclusion criteria listed above will be excluded from participating in the trial.

Related Conditions & MeSH terms

• hCG

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Gynuity Health Projects	Stanford University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	hCG trends	To ascertain the proportion of women with decreases in hCG between 56-84 days gestation	Between 56-84 days gestation